Skip to main content
AACR Project GENIE v19.0 · 21,017 myeloid samples Panel-adjusted Fisher's exact with Benjamini-Hochberg FDR N=1 case study · Not clinical guidance

SKI Domain Analysis

SETBP1 SKI homology domain hotspot mapping and co-occurrence

SKI Domain
193 patients
Hotspot positions 858-871
Non-SKI
29 patients
G870S Rank
#2
136 samples (88 patients), after D868N (195 samples)
G870S in SKI
40%
88 of 221 SKI-mutated patients (GENIE myeloid recount)
DNMT3A-EZH2
0.999 STRING
Top score, tied with 2 other pairs

SKI vs Non-SKI Co-occurrence

Figure 2 | SETBP1 SKI domain co-occurrence comparison

Source: GENIE v19.0

Loading protein domain plot...
Figure 3 | SETBP1 protein domain architecture with mutation hotspots

Source: GENIE v19.0 sample counts; AT-hooks from UniProt Q9Y6X0

SKI Domain Hotspot Map

The SETBP1 mutation hotspot 1
[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
spans codons 858-871 and contains the beta-TrCP degron (D-S-G-I-G-T, residues 868-873 in UniProt Q9Y6X0). Somatic SETBP1 mutations in myeloid malignancies 2
[2] H 2013
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013)
cluster at key residues: D868, S869, G870, I871. Mutations at these positions disrupt degron recognition by the SCF(beta-TrCP) E3 ubiquitin ligase complex, preventing ubiquitination and proteasomal degradation. The result is nuclear SETBP1 accumulation, which inhibits PP2A tumor suppressor activity 1
[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
and upregulates HOXA9/HOXA10 transcription factors — a key oncogenic axis in myeloid neoplasms.
PositionWildtypeMost Common MutationGENIE samplesMechanism
858EE858K5Degron disruption
868DD868N195Degron disruption
869SS869R (also S869N, S869G: 3 each)5Degron disruption
870GG870S136Degron disruption
871II871T28Degron disruption
Source: Degron motif: DpSGxxS recognized by beta-TrCP 1
[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
2
[2] H 2013
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013)
.

SETBP1 Pairwise Partners

PartnerCo-mutatedO/Ep-valueDirection
CSF3R1810.001.1e-13Co-occurring
CBL324.857.1e-14Co-occurring
ASXL11454.674.4e-71Co-occurring
EZH2364.073.8e-13Co-occurring
SRSF2793.736.4e-27Co-occurring
U2AF1393.465.8e-12Co-occurring
GATA2112.540.004Co-occurring
PTPN11152.519.6e-4Co-occurring
NRAS292.196.9e-5Co-occurring
RUNX1391.954.2e-5Co-occurring
IDH110.130.005Mutually exclusive
NPM120.163.6e-4Mutually exclusive
JAK2140.428.3e-5Mutually exclusive
TP53140.550.014Mutually exclusive
DDX4124.260.079Neutral
SMC343.250.034Neutral
RAD2141.730.295Neutral
STAG2111.680.102Neutral
ZRSR261.450.311Neutral
BCOR91.090.719Neutral
KRAS81.050.851Neutral
DNMT3A301.040.840Neutral
TET2340.930.714Neutral
PHF650.931.000Neutral
IDH2120.920.885Neutral
MPL30.841.000Neutral
FLT3100.810.556Neutral
SF3B180.590.120Neutral
CALR40.530.258Neutral
CEBPA20.440.332Neutral
WT130.420.124Neutral
BCORL100.000.036Neutral
SMC1A00.000.639Neutral
Source: Fisher's exact test (two-sided) with Benjamini-Hochberg correction. Panel-adjusted denominators. GENIE v19.0 17
[17] Consortium 2017
AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017)
, 222 SETBP1-mutated patients (GENIE myeloid and histiocytic cancer types, one sample per patient).

EZH2 Interaction

STRING v12.0 protein-protein interaction analysis reveals DNMT3A-EZH2 with the top confidence score in the network (0.999, tied with DNMT3A-DNMT3L and U2AF1-SRSF2 among 77 interactions), and the strongest link between two of the patient's mutated genes. Both are epigenetic regulators — DNMT3A controls DNA methylation, EZH2 controls histone methylation (H3K27me3) 9
[9] T 2010
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010)
10
[10] A 2020
Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020)
. Their co-mutation creates a bidirectional epigenetic collapse: loss of DNA methylation fidelity (DNMT3A R882H) combined with loss of Polycomb-mediated gene silencing (EZH2 V662A LoF).
SETBP1 connects to this axis as an epigenetic hub 3
[3] R 2018
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nat Commun (2018)
through HCF1/KMT2A interaction and PP2A inhibition 1
[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
leading to HOXA9/HOXA10 upregulation. Runx1 repression 5
[5] BA 2016
Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development. Leukemia (2016)
further compounds the transcriptional deregulation. With both DNMT3A (which also upregulates HOXA via hypomethylation) and SETBP1 converging on HOXA, the oncogenic signaling is amplified.
The Jaccard pathway similarity of SETBP1-IDH2 (0.588) and DNMT3A-IDH2 (0.590) is nearly identical. IDH2 and SETBP1 are not mutually exclusive in this GENIE dataset (O/E 0.92, not significant; see the partner table), so these values say nothing about an exclusivity mechanism.
Recent evidence that SETBP1 can act as a first-hit driver 4
[4] I 2024
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood (2024)
in myeloproliferative disorders with bone marrow fibrosis expands the mechanistic framework: SETBP1 mutations may not only cooperate with pre-existing epigenetic lesions but can independently initiate clonal expansion.
Source: STRING v12.0 protein-protein interaction database. Jaccard similarity computed from Reactome and KEGG pathway memberships.

Research Context

Piazza et al. (2013) found 92% of SETBP1 mutations in their series at codons 858-871. In GENIE v19.0 myeloid data, 90.7% of SETBP1 coding mutation calls (431 of 475) fall there. G870S is the second most common hotspot variant (136 samples, 88 patients), after D868N (195 samples, 101 patients). SKI-domain mutations show consistently amplified co-occurrence ratios compared to non-SKI mutations: CSF3R O/E rises from 10.00 overall to 10.76 within the SKI subset, and CBL from 4.85 to 5.41. The SKI domain hotspot defined by Makishima et al. (2013) concentrates mutations at positions associated with monosomy 7 and poor prognosis. The SKI-domain enrichment pattern (193 of 222 SETBP1-mutated patients) validates the biological significance of this region.
References
  1. Piazza R et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013). PubMed
  2. Makishima H et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013). PubMed
  3. AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov (2017). DOI
  4. Piazza R et al. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nat Commun (2018). PubMed
  5. Crespiatico I, Zaghi M, Mastini C, et al. (senior author Piazza R). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood (2024). PubMed
  6. Ernst T et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010). PubMed
  7. Vishwakarma BA et al. Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development. Leukemia (2016). PubMed
  8. Chase A, Score J, Lin F, et al. Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia (2020). DOI